Publications
Detailed Information
Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Kim, Min A. | - |
dc.contributor.author | Jordan, Bruce | - |
dc.contributor.author | Pickl, Marlene | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Lee, Hyuk Joon | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Kim, Woo Ho | - |
dc.contributor.author | Yang, Han-Kwang | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:08:46Z | - |
dc.date.available | 2021-01-31T11:08:46Z | - |
dc.date.created | 2020-12-23 | - |
dc.date.created | 2020-12-23 | - |
dc.date.created | 2020-12-23 | - |
dc.date.created | 2020-12-23 | - |
dc.date.issued | 2011-06 | - |
dc.identifier.citation | Diagnostic Molecular Pathology, Vol.20 No.2, pp.94-100 | - |
dc.identifier.issn | 1052-9551 | - |
dc.identifier.other | 119684 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173057 | - |
dc.description.abstract | Despite recent advances in chemotherapy, the prognosis for patients with advanced gastric cancer (GC) or gastroesophageal junction cancer remains poor. Human epidermal growth factor receptor 2 (HER2) is a novel target for biologic therapy in metastatic GC. We analyzed the association between HER2 overexpression and the clinicopathologic characteristics of advanced GC. Formalin-fixed, paraffin-embedded tumor samples were collected from patients with stage III or to IV (M-0) GC who subsequently underwent curative surgery followed by adjuvant chemotherapy with 5-fluorouracil and cisplatin. All the samples were analyzed for HER2 status by immunohistochemistry (IHC) and fluorescence in situ hybridization. Of 142 samples analyzed, 7.1% scored IHC 2+ and 8.6% scored IHC 3+, whereas 9.3% were HER2-amplified. Of HER2-amplified cases, 76.9% (10/13) scored IHC 3+, showing the correlation between HER2 amplification and overexpression (P = 0.01). HER2 IHC 3+ cases were more common in the intestinal-type tumors compared with diffuse-type tumors (16.7% vs. 5.1%, respectively; P = 0.049), and a nonsignificant trend was observed using fluorescence in situ hybridization (14.3% vs. 9.2%, respectively; P = 0.399). HER2 gene amplification was more frequent in stage IV (M-0) than stage III disease (15.4% vs. 4.0%, respectively; P = 0.037). Interestingly, HER2-amplified disease was more common than nonamplified disease in patients with nodal stage 3 tumors (76.9% vs. 38.6%, respectively; P = 0.009); a similar pattern was observed using IHC. HER2 overexpression correlated with nodal stage, and a lymph node ratio greater than 0.5 was more common in HER2-amplified tumors than HER2-nonamplified tumors (69.2% vs. 43.3%, respectively; P = 0.086). These findings suggest that further investigations of adjuvant therapy with HER2-targeted therapy for advanced GC are warranted. | - |
dc.language | 영어 | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1097/PDM.0b013e3181fc02b7 | - |
dc.citation.journaltitle | Diagnostic Molecular Pathology | - |
dc.identifier.wosid | 000290662100005 | - |
dc.identifier.scopusid | 2-s2.0-79958066203 | - |
dc.citation.endpage | 100 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 94 | - |
dc.citation.volume | 20 | - |
dc.identifier.sci | 000290662100005 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Lee, Hyuk Joon | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Kim, Woo Ho | - |
dc.contributor.affiliatedAuthor | Yang, Han-Kwang | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GENE AMPLIFICATION | - |
dc.subject.keywordPlus | TYROSINE KINASE | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | immunohistochemistry | - |
dc.subject.keywordAuthor | fluorescence in situ hybridization | - |
dc.subject.keywordAuthor | gastric cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.